英創遠達製藥 CASI 深 滬
已收盤 08-08 16:00:00 美东时间
1.63
+0.160
+10.88%
華盛通- 最 高1.7199
- 今 開1.47
- 成交量 23.24万股
- 最 低 1.4553
- 昨 收 1.47
- 總市值 2525.33万
- 52周最高 7.67
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.0909
- 委 比 30.46%
- 總股本 1549.28万
- 歷史最高 88.92
- 量 比 0.02
- 振 幅 18.00%
- 歷史最低 1.0909
- 每 手 1
- 風險率 1.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Century Casinos, Inc. Announces Second Quarter 2025 Results
Company Initiates Strategic Review Process to Enhance Shareholder Value. COLORADO SPRINGS, Colo., Aug. 7, 2025 /PRNewswire/ -- Century Casinos, Inc. (the "Company", "we", "us", or "our") (Na...
08-07 18:00
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as Chief Medical Officer. With over 25 years of experience in developing therapies for epilepsy and other neurological disorders, Dr. Hulihan will focus on advancing simufilam, a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy. The clinical study for simufilam is expected to begin in H1 2026. Dr. Hulihan previously served as CMO at Marinus Pharmaceuticals and held s...
08-07 11:30
CASI Pharmaceuticals shares are trading higher after the company announced FDA clearance for CID-103.
CASI Pharmaceuticals shares are trading higher after the company announced FDA ...
08-04 23:39
CASI Pharmaceuticals Appoints David Cory as CEO to Drive CID-103 Program
CASI Pharmaceuticals ( ($CASI) ) has issued an announcement. On July 21, 2025, ...
07-22 18:28
CASI Pharmaceuticals announces CEO appointment
CASI Pharmaceuticals (NASDAQ:CASI) has named David Cory as its new chief executive officer and board member. Wei-Wu He, Ph.D., will step down as CEO and transition to the role of executive chairman of...
07-22 04:21
ISS National Lab's Orbital Edge Accelerator Program Selects Six Startups
Each startup to receive up to $500,000 in investment and future research opport...
07-17 03:58
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday?
Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating DM1.
06-17 22:56
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and maintains $4 price target.
05-19 18:43
CASI Pharmaceuticals Q1 EPS $(0.69) Misses $(0.61) Estimate, Sales $6.24M Beat $6.10M Estimate
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.61) by 13.11 percent. This is a 2.82 percent increase over losses of $(0.71) per share
05-17 06:06
